Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 440 participants.

Also called NCT06814145

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 440 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06814145
  • WHO UTN U1111-1309-2142
  • EU CT 2024-515773-99-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Belgium, Canada, France, Germany, Israel, Italy, Mexico, Poland, Spain, Sweden, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06814145. Randomized; no masking; primary purpose treatment. Start 2025-04-16 (actual); primary completion 2035-08-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
Acronym
HARMONIZE
Condition
Hypertension, Pulmonary
Intervention (Biological)
Sotatercept
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct06814145
Content hash
7527f97b8a76353350380c492159ef2d83fbd9a1f24c677f62c70c8570cee009